Kiora Pharmaceuticals (NASDAQ:KPRX) Trading Down 0.5% – Should You Sell?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) traded down 0.5% during mid-day trading on Tuesday . The company traded as low as $2.02 and last traded at $2.06. 28,760 shares were traded during mid-day trading, a decline of 43% from the average session volume of 50,870 shares. The stock had previously closed at $2.07.

Analyst Ratings Changes

Several research analysts have recently commented on KPRX shares. Zacks Research cut shares of Kiora Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Kiora Pharmaceuticals in a research report on Tuesday, September 2nd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a research report on Friday, October 31st. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Kiora Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $10.00.

Kiora Pharmaceuticals Stock Performance

The stock has a market cap of $7.58 million, a price-to-earnings ratio of -0.99 and a beta of -0.75. The stock has a fifty day simple moving average of $2.34 and a two-hundred day simple moving average of $2.67.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its quarterly earnings data on Friday, November 7th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.73. Equities analysts expect that Kiora Pharmaceuticals, Inc. will post 1.28 earnings per share for the current fiscal year.

Institutional Trading of Kiora Pharmaceuticals

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Citadel Advisors LLC purchased a new position in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 44,573 shares of the company’s stock, valued at approximately $125,000. Citadel Advisors LLC owned approximately 1.21% of Kiora Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 76.97% of the stock is owned by hedge funds and other institutional investors.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.